Geriatric Drugs and Disease Management Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027

Report Code: HCR 0959 Report Format: PDF + Excel

Geriatric Drugs and Disease Management Market Overview

Geriatric Drugs and Disease Management Market Size is estimated to reach $3.1 billion by 2027 and is poised to grow at a CAGR of 7.1% over the forecast period of 2022-2027. The geriatric is a rapidly developing medical specialty that deals with the diagnosis, treatment and prevention of disorders in the elderly population. The population usually consists of patients aged 60 years and above. According to the Department of Economics and Social Affairs, in 2019 there are 703 million persons aged 65 years or over in the world and by 2050 one in six people in the world will be over age 65. Also, owing to elder age and weaken immunity, there is a high risk of various diseases and infections in geriatric patients Such a growing geriatric population and risk of diseases and infections create demand for various drugs such as analgesic, antihypertensive, antidiabetic, antipsychotic, anticoagulant, antidepressant and others. The requirements of the aged population in terms of healthcare are increasingly being prioritized by governments over the world. In order to do this, a number of supportive healthcare policies have been actively put into effect. Additionally, key market players in the healthcare industry launched new products in the market to minimize severe symptoms of diseases. Such availability of essential medicines and supporting government policies fuel the growth of the Geriatric Drugs and Disease Management Industry over the forecast period 2022-2027.

Geriatric Drugs and Disease Management Market Report Coverage

The report: “Geriatric Drugs and Disease Management Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments in the Geriatric Drugs and Disease Management Market.

by Therapeutic: Analgesic, Antihypertensive, Statins, Antidiabetic, Proton pump inhibitors (PPI), Anticoagulant, Antipsychotic, Antidepressant and Others.
by Condition: Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, Respiratory and Others.
by Route of Administration: Oral, Parentals and Others.
by Geography: North America (U.S., Canada and Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021, owing to the developed healthcare infrastructure and high spending on healthcare for the elderly population fueling the growth of the Geriatric Drugs and Disease Management Market Size in this region.
  • The Geriatric Drugs and Disease Management Market is predicted to increase owing to the increased risk of various diseases in the geriatric population.
  • However, the high price of drugs and the chances of side effects of medicines in elderly people may limit market growth over the forecast period 2022-2027.
  • A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Geriatric Drugs and Disease Management Market Report.

Geriatric Drugs and Disease Management Market: Market Share (%) by region, 2021

Geriatric Drugs and Disease Management Market

For More Details on This Report - Request for Sample

Geriatric Drugs and Disease Management Market Segment Analysis- by Therapeutic

Geriatric Drugs and Disease Management Market based on Therapeutic can be further segmented into Analgesic, Antihypertensive, Statins, Antidiabetic, Proton pump inhibitors (PPI), Anticoagulant, Antipsychotic, Antidepressants and Others. Analgesic held a dominant share in the year 2021. This is the result of growing pain-related diseases in the geriatric population. According to the research paper published in National Center for Biotechnology Information (NCBI) in 2022, a considerable portion of the older population is affected by chronic pain, which can lead to functional disability. It is frequently accompanied by associated psychiatric illnesses including depression and anxiety, as well as cognitive dysfunction and sleep disturbances. Such relation of chronic pain with other disease create demand for analgesic and drive the growth of the Geriatric Drugs and Disease Management Market Size.

However, the Antidiabetic segment is estimated to grow with the fastest CAGR rate of 7.3% over the forecast period 2022-2027. This is owing to the growing burden of diabetics in the elderly population and diabetes-associated disease & health complications. As per the research article published in American Diabetics Association in 2021, Over one-quarter of people over the age of 65 years have diabetes and one-half of older adults have prediabetes. Also, older adults with diabetes have higher rates of premature death, functional disability, accelerated muscle loss and coexisting illnesses, such as hypertension, coronary heart disease and stroke, than those without diabetes. Such growing prevalence of diabetes in the geriatric population and risk of associated diseases surge demand for antidiabetic drugs and fuel growth of the Geriatric Drugs and Disease Management Market Share over the forecast period 2022-2027.

Geriatric Drugs and Disease Management Market Segment Analysis- by Condition

Geriatric Drugs and Disease Management Market based on the condition can be further segmented into Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, Respiratory and Others. The cardiovascular segment held a dominant market share in the year 2021. This is attributed to the growing cases of obesity in the geriatric population owing to a long illness, bedrest and the effect of various drugs. Such conditions increase the risk of cardiovascular disease, in the geriatric population. According to the National Institute of Aging people with age 65 and older are much more likely than younger people to suffer a heart attack, have a stroke, or develop coronary heart disease and heart failure. Such a growing risk of cardiovascular disease in the elderly population fuel the growth of the Geriatric Drugs and Disease Management Market Share over the forecast period 2022-2027.

However, Cancer is estimated to grow with the fastest CAGR rate of 7.7% over the forecast period 2022-2027. This is owing to the growing prevalence of cancer in the elderly population. According to Cancer Research U.K, the peak rate of cancer cases is high in the elderly population and mostly found in ages between 85-89 years. As per National Cancer Institute, As of January 2022, it is estimated that there are 18.1 million cancer survivors in the United States. And the number of cancer survivors is projected to increase by 24.4%, to 22.5 million, by 2032. Such a growing number of cancer cases and a growing population of cancer survivors surge demand for analgesic, antihypertensive, statins, antidiabetic, proton pump inhibitors (PPI), anticoagulants, antipsychotics, antidepressants and other drugs for cancer treatment and associated diseases. Such growing demand for drugs by the geriatric population drives the growth of the Geriatric Drugs and Disease Management Market Share over the forecast period 2022-2027.

Geriatric Drugs and Disease Management Market Segment Analysis- by Geography

The Geriatric Drugs and Disease Management Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 33% in the year 2021. This is owing to the best healthcare facilities available in this region and the high spending capacity of the elderly population. Also, various presence of various elder care services and technology like telemedicine drive the growth of the geriatric drugs and disease management industry. Also, according to the Center for Disease Control and Prevention (CDC), in the United States, there are 26.4 million people aged 65 years or older (48.8%) have prediabetes. Such growing cases of various chronic diseases surge demand for analgesic, antihypertensive, statins, antidiabetic, proton pump inhibitors (PPI), anticoagulants, antipsychotics, antidepressants and other drugs & treatments which fuel the growth of the Geriatric Drugs and Disease Management Market Size.

Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR rate of 6.9% over the forecast period 2022-2027. According to United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), about 59 percent of the geriatric population lives in the Asia-Pacific region. Also, more than 1.3 billion peoples with age 60 and over live in Asia-Pacific by 2050. Such a growing aging population and high risk of various diseases in this age propel the growth of the Geriatric Drugs and Disease Management Market Size in this region over the forecast period 2022-2027.

Geriatric Drugs and Disease Management Market Drivers

Growing Importance of Geriatric Medicines is Anticipated to Fuel Market Growth.

In order to maintain and manage the numerous medical, cognitive, social and psychological problems that older people face, geriatric medicine (GM) such as analgesic, antihypertensive, statins, antidiabetic and proton pump inhibitors (PPI), anticoagulant, antipsychotic, antidepressant and others play an important role. The increase in growth of the senior population, the high frequency of chronic diseases including cancer and rheumatoid arthritis among the elderly and higher spending on medications contribute to the geriatric drugs and the disease management industry. The elderly population spends a lot of money on healthcare. Nearly seven times the national average of $14,000 and responsible for 35% of all medical spending, those in the top 5% of total expenditures spend about $98,000 annually. Such higher spending on Medicare by the elderly population drives the Geriatric Drugs and Disease Management Industry over the forecast period 2022-2027.

Rising Incidence of Chronic Disease in Elderly Population is Driving the Market Growth.

In the elderly population, there is a high risk of disease and infection than in adults. For instance, as per a research paper published in ‘Karger’ in February 2019, in people above 75 years old, there was an increase by 65% in the total number of stroke events (+66% in men and +65% in women). Also, as per a research article published in BMC public health in 2019, Fifty-one studies from 16 States of India were included as 56 datasets, which anticipated the prevalence of depression among the Indian elderly population as 34.4%. Such a growing incidence of chronic disease drives the growth of the Geriatric Drugs and Disease Management Industry.

Geriatric Drugs and Disease Management Market Challenge

High Prices of Medicines are Hampering Market Growth

People with older age are low in immunity and have various disease conditions such as cardiovascular, arthritis, neurological, cancer, osteoporosis, respiratory and others. Such cases of diseases or combinations of diseases need various medicines. In the United States, pharmaceutical companies are able to set the price of a prescription drug at whatever they believe the market will bear. A 2021 study by the RAND Corporation compared prices for prescription drugs in the United States with those in 32 other countries, including the United Kingdom, Germany and Australia; the authors ultimately found that prices in the United States were an average of 156 percent higher than prices in the comparison countries. According to GoodRx, drug companies increased the prices of 832 drugs by an average of 4.5 percent in January 2021 and 67 drugs by an average of 3.5 percent in July 2021. Such high prices of drugs may hinder the growth of the Geriatric Drugs and Disease Management Market.

Geriatric Drugs and Disease Management Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Geriatric Drugs and Disease Management Market. The top 10 companies in the Geriatric Drugs and Disease Management Market are:

  1. Merck & Co. Inc.
  2. Geriatric & Medical Companies Inc.
  3. Senior Care Centers of America Inc.
  4. GGNSC Holdings LLC
  5. UAS Laboratories.
  6. AstraZeneca
  7. Boehringer Ingelheim GmbH
  8. Novartis AG
  9. Sanofi S.A.
  10. GlaxoSmithKline plc.

Recent Developments

  • In July 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.
  • In October 2021, Merck & Co. Inc. published preliminary results of the clinical trials for its Molnupiravir anti-COVID-19 drug. As per the findings, patients administered with these anti-viral halved chances of hospitalization among patients exhibiting mild or moderate symptoms. Those administered with this drug showed 100% recovery.
  • In December 2020, AstraZeneca, Greater scientific presence in immunology by adding Alexion's innovative complement-technology platforms and strong pipeline dedicated to rare disease units to be headquartered in Boston announced a partnership with Alexion. Acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalize Alexion’s portfolio.

Relevant Titles

Incontinence Products Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast

Report Code: HCR 0136

Elderly Care Products and Services Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast

Report Code: HCR 1371

Antihypertensive Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast

Report Code: HCR 0143

For more Lifesciences and Healthcare Market reports, please click here

1. Geriatric Drugs and Disease Management Market - Overview
    1.1 Definitions and Scope
2. Geriatric Drugs and Disease Management Market - Executive Summary
3. Geriatric Drugs and Disease Management Market - Comparative Analysis
    3.1 Company Benchmarking – Key Companies
    3.2 Global Financial Analysis – Key Companies
    3.3 Market Share Analysis – Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Geriatric Drugs and Disease Management Market - Start-up Companies Scenario Premium
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Geriatric Drugs and Disease Management Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Geriatric Drugs and Disease Management Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 PorterFive Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Geriatric Drugs and Disease Management Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Geriatric Drugs and Disease Management Market – by Therapeutic
    8.1 Analgesic
    8.2 Antihypertensive
    8.3 Statins
    8.4 Antidiabetic
    8.5 Proton pump inhibitors (PPI)
    8.6 Anticoagulant
    8.7 Antipsychotic
    8.8 Antidepressant
    8.9 Others
9. Geriatric Drugs and Disease Management Market – by Condition
    9.1 Cardiovascular
    9.2 Arthritis
    9.3 Neurological
    9.4 Cancer
    9.5 Osteoporosis
    9.6 Respiratory
    9.7 Others
10. Geriatric Drugs and Disease Management Market – by Application
    10.1 Full-Service Restaurants
    10.2 Quick Service Restaurants
    10.3 Others
11. Geriatric Drugs and Disease Management Market – by Route of Administration
    11.1 Oral
    11.2 Parentals
    11.3 Others
12. Geriatric Drugs and Disease Management Market - by Geography
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Geriatric Drugs and Disease Management Market - Entropy
14. Geriatric Drugs and Disease Management Market – Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Geriatric Drugs and Disease Management Market – Key Company List by Country Premium Premium
16. Geriatric Drugs and Disease Management Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.